A recent study has reported a potential connection between cancer development and a subtype of myasthenia gravis (MG). The study, conducted in Italy, revealed the presence of muscle-specific kinase (MuSK) protein in tumor samples from patients with MuSK myasthenia gravis (MuSK-MG). The data also indicated a higher likelihood…
News
UCB’s injection therapy Zilbrysq (zilucoplan) has gained approval in Canada for treating adults with generalized myasthenia gravis (gMG) who are positive for antibodies targeting the acetylcholine receptor (AChR). The decision by Health Canada was supported by results from the Phase 3 RAISE trial (NCT04115293), in which the…
An under-the-skin, or subcutaneous, injectable form of efgartigimod alfa has been approved in China to treat adults with generalized myasthenia gravis (gMG) who test positive for antibodies against the acetylcholine receptor. The therapy was approved as an add-on to standard gMG treatment. This subcutaneous formulation of efgartigimod (efgartigimod…
Adolescent girls with juvenile myasthenia gravis (JMG) were more likely to have enlarged thymus glands than younger girls and adults with myasthenia gravis (MG), according to a retrospective study in France. The higher levels of female hormones during puberty may explain these results, the researchers noted, supporting the potential…
The incidence and prevalence of myasthenia gravis (MG) among the population in France are higher than reported for other European countries. That’s according to a retrospective population-based study, which also found the incidence of MG tended to increase with age and was associated with a higher risk of cancer.
Treatment with nipocalimab led to significant reductions in disease severity among people with generalized myasthenia gravis (gMG), as assessed by a drop in the MG Activities of Daily Living (MG-ADL) score, according to top-line data from a pivotal Phase 3 trial. Findings from the trial, dubbed VIVACITY-MG3…
Treatment with the investigational CAR T-cell therapy Descartes-08 led to deep and sustained reductions in disease severity among generalized myasthenia gravis (gMG) patients, according to top-line data from a Phase 2b clinical trial. The therapy, designed somewhat differently than others in its class, also avoided some of the potentially…
Harbour BioMed has submitted a new, revised version of a biologics license application (BLA) to China’s regulatory agency requesting the approval of batoclimab (HBM9161) to treat generalized myasthenia gravis (MG). The original application was accepted for review last year by China’s National Medical Products Administration (NMPA). The…
Patients who received Vyvgart (efgartigimod alfa) as part of an expanded access program required more frequent dosing to treat generalized myasthenia gravis (gMG) than what was used during clinical testing, according to a small study in the Netherlands. Study findings also showed that more than half of the…
People with myasthenia gravis (MG) who have more active disease are at a higher risk of having an exacerbation, or a sudden worsening of symptoms, a new study from Germany has found. Even after appropriate treatment for an exacerbation, this group of MG patients remained clinically more impaired, the…
Recent Posts
- New study explores when MG patients can taper immunosuppressive therapy
- Thymus gland removal seen as effective option for late-onset MG
- A caregiver’s perspective on his wife’s health after breast reduction
- My twin loves junk food, but a veggie and fruit diet is helping him combat MG
- My secret book of survival in life with myasthenia gravis